ERSPC

From Cancer Guidelines Wiki

ERSPC



Publications of this clinical trial

  1. Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2014 Feb;65(2):329-36 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23954085. (compare appraisals of this publication)
  2. Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008 Sep;54(3):581-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18423977. (compare appraisals of this publication)
  3. Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 2013 Nov;64(5):703-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721957. (compare appraisals of this publication)
  4. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010 Aug;11(8):725-32 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20598634. (compare appraisals of this publication)
  5. Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013 May 15;105(10):719-25 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23479454. (compare appraisals of this publication)
  6. Kilpeläinen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer 2011 Dec;47(18):2698-705 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21788129. (compare appraisals of this publication)
  7. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007 Jul;52(1):89-97 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17257742. (compare appraisals of this publication)
  8. Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, et al. Screening for prostate cancer: results of the rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol 2013 Oct;64(4):530-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23759326. (compare appraisals of this publication)
  9. Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012 Nov;62(5):745-52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22704366. (compare appraisals of this publication)
  10. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012 Mar 15;366(11):981-90 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22417251. (compare appraisals of this publication)
  11. Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009 Nov;56(5):753-60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19682790. (compare appraisals of this publication)

Compare all appraisals of this clinical trial


Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Clinical_trial:ERSPC&oldid=87246"